title: Ovarian transposition for stage Ib squamous cell cervical cancer - lack of effects on survival rates?
abstract: BACKGROUND
  To investigate the impact of ovarian transposition (OT) on survival rates of the patients with stage Ib squamous cell cervical cancer.
  
  
  METHODS
  Ninety-two subjects who underwent a radical hysterectomy including oophorectomy were evaluated. For nineteen (20.7%) , OT was performed. Patients were divided into two groups, OT versus oophorectomy alone. The primary end-point of this study was to investigate the impact of OT on tumor recurrence rate and time, 5-year disease-free survival (DFS) and overall survival (OS) . These comparisons were performed for subgroups including patients who received radiotherapy versus who did not. Statistical analyses were conducted using the Chi-square test, T-test and Mann-Whitney test. OS was examined using the Kaplan-Meier method. P ≤ 0.05 was considered to be statistically significant.
  
  
  RESULTS
  The median follow-up period was 89 months for OT and 81 months for the oophorectomy group (p>0.05). Both groups experienced similar recurrence rates (31.6% vs. 26.4%, p=0.181). The median duration from surgery to recurrence, and surgery to death were also similar between the groups (p>0.05). The 5-year DFS and OS rates were both 68.4% for the OT group, and 73.6% and 77.8% for the oophorectomy group (p=0.457 and p=0.307, respectively). While the 5-year DFS rate was not statistically significant between the OT and oophorectomy groups who did not receive radiotherapy (p=0.148), the 5-year OS rate was significantly higher in the oophorectomy group (95.4% vs 66.7%, respectively) without radiotherapy (p=0.05). The 5-year DFS and OS rates were statistically similar between the groups who received adjuvant radiotherapy (p>0.05).
  
  
  CONCLUSIONS
  Ovarian transposition has not significantly negative effect on the survival rates when adjuvant radiotherapy will be applied, while 5-year OS may be less in OT group if radiotherapy is not mandatory.
authors.affiliation: Etlik Zubeyde Hanim Women's Health Education and Research Hospital, Division of Gynecological Oncology, Ankara, Turkey.
authors.forename: A Taner
authors.initials: AT
authors.lastname: Turan
authors.forename: H Levent
authors.initials: HL
authors.lastname: Keskin
authors.forename: Betul
authors.initials: B
authors.lastname: Dundar
authors.forename: Burcu
authors.initials: B
authors.lastname: Gundogdu
authors.forename: Nejat
authors.initials: N
authors.lastname: Ozgul
authors.forename: Nurettin
authors.initials: N
authors.lastname: Boran
authors.forename: Gokhan
authors.initials: G
authors.lastname: Tulunay
authors.forename: M Faruk
authors.initials: MF
authors.lastname: Kose
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007044:Hysterectomy; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D059351:Organ Sparing Treatments; D010052:Ovariectomy; D010053:Ovary / Q000601:surgery*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D018709:Statistics, Nonparametric; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*